Pharma sector company Cipla has released the results for the July-September quarter of the financial year 2025. Today, this stock is witnessing a decline since the time of early business. However, the decline was seen to reduce soon after the results were released. Today, only pharma stocks are witnessing a decline. The Nifty Pharma index was among the sectoral indices with the biggest decline. Talking about Cipla's second quarter results, growth has been seen in the figures on a year-on-year basis. These figures have been better than expected.

Cipla's profit in the September quarter has increased by 12.9% year-on-year. During this period, the company's income has also shown a growth of 7%. Whereas, there has been an improvement in operating profit (EBITDA). The margin has been better than expected.

Income and profit figures During July-September, Cipla's consolidated profit is at ₹ 1,305 crores as compared to ₹ 1155 crores in the second quarter of the previous financial year. In the CNBC-TV18 poll, it was estimated to be ₹ 1,208 crores. Similarly, consolidated income also grew year-on-year to ₹ 7,151 crores. In the same quarter of the previous financial year, the company's income was ₹ 6,678 crores. It was estimated to be ₹ 6,968 crores. Talking about the sales in the US business  and operating profit, it is also better than expected. The company's EBITDA increased from ₹1,734 crore to ₹1,886 crore. It was estimated to be ₹1,776 crore. The company's margin was 26.8% as against 25.9%. The margin was estimated to be 26%. US sales were $237 million. It was estimated to be $235 million. The company's business in India grew 5% year-on-year. Cipla said that it is investing ₹385 crore in research and development, which has increased by about 5.5% of total sales. It has seen a growth of 2% on an annual basis. The company had a net cash position of ₹7,950 crore. The consumer health business has seen a growth of 21%. The company said that during the July-September quarter, sales of anti-infectives have slowed down. During the second quarter of the last financial year, it had seen a growth of 12%, which has now come down to 4.9%. However, the respiratory, cardiac and urology segments have seen tremendous growth. Cipla's Managing Director and Global CEO, Umang Vohra, along with the results, said that the margin has reached an all-time high on the back of better mix and operational efficiency. There was some impact on the business due to seasonal changes in India.